Gregory Monohan, MD

Gregory Monohan was born in Lexington and spent his youth growing up in Winchester, KY. He graduated cum laude from Transylvania University then subsequently graduated with distinction from the University of Kentucky College of Medicine in May 2000. Dr Monohan completed Internal Medicine residency at Indiana University in Indianapolis, IN. He later returned to Lexington and the University of Kentucky for Hematology and Medical Oncology fellowship training.
After fellowship, Dr Monohan joined the Hematology and Medical Oncology Division as faculty in 2006 with a clinical and academic focus in blood cancers, specifically multiple myeloma. Dr Monohan is a self-described clinician educator. He served from 2011 until 2022 as the hematology and medical oncology Fellowship Program Director. He has also spent the past 13 years as clinical director for the Hematologic and Lymphatic Systems medical school course.
In 2019, he matriculated to Clinical Professor of Medicine. His administrative activities included stepping in as the Interim Chief of the Division of Hematology, Blood and Marrow Transplantation from 2022-2025. He is currently serving as the Associate Division Director for Clinical Operations and Patient Experience.
During his time at the University of Kentucky, Dr Monohan has completed more than 500 bone marrow transplants, mostly in patients with multiple myeloma. His practice expanded to include immunotherapies such as CAR-T cellular therapy and bi-specific antibodies. He has been the principal investigator on two dozen clinical trials, given hundreds of medical school and resident lectures, and submitted dozens of abstracts and poster for local, regional, and national presentations. Aside from his children’s activities, he is a UK sports and horse racing enthusiast.
Financial relationships
-
Attribution:SelfType of financial relationship:StockIneligible company:Johnson & JohnsonTopic:Equity InterestDate added:01/22/2026Date updated:01/22/2026
-
Attribution:SelfType of financial relationship:StockIneligible company:Quest DiagnosticsTopic:Equity InterestDate added:01/22/2026Date updated:01/22/2026
-
Attribution:SelfType of financial relationship:StockIneligible company:DuPontTopic:Equity InterestDate added:01/22/2026Date updated:01/22/2026Relationship end date:07/01/2025
-
Attribution:SelfType of financial relationship:StockIneligible company:PfizerTopic:Equity InterestDate added:01/22/2026Date updated:01/22/2026Relationship end date:07/01/2025
-
Attribution:SelfType of financial relationship:StockIneligible company:NovartisTopic:Equity InterestDate added:01/22/2026Date updated:01/22/2026Relationship end date:03/01/2025

Facebook
X
LinkedIn
Forward